Biomedical subjects

Asher Chanan-Khan

Publications and source records attributed to Asher Chanan-Khan.

22 records · Page 2Linked to original sources

PubMed2002

Radioimmunotherapy in non-Hodgkin lymphoma.

Targeted therapy using monoclonal antibodies against a tumor-specific antigen is now an established mode of therapy in the management of malignant lymphomas. Radioimmunotherapy, a novel way of delivering systemic radiotherapy concurrently with immunotherapy, has finally appeared on the horizon, with promising results. Recent clinical trials have demonstrated the safety and efficacy of radioimmunoconjugates. Durable antitumor responses have been achieved, even in heavily pretreated patients. The optimal position that these novel agents should take in the algorithm of lymphoma therapy remains to be defined.

Algorithms↗

PubMedDate not supplied

Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART.

PURPOSE: The gastrointestinal (GI) tract is the most common site of extranodal disease in patients with systemic non-Hodgkin's lymphoma (NHL). Patients with systemic NHL and GI involvement associated with AIDS (GI-ARL) have a significantly worse prognosis than those without AIDS. We studied whether the introduction of HAART is associated with improved survival in patients with GI-ARL. PATIENTS AND METHOD: 36 patients with GI-ARL were identified from the tumor registries of a large municipal hospital in New York City and a tertiary care facility in western New York State. Of these, 28 patients did not receive HAART and 8 were treated with HAART. The primary endpoint was survival, which was defined as time from date of diagnosis of NHL until death from any cause. RESULTS: Patients were analyzed based on whether or not they were treated with HAART. Kaplan-Meier analysis showed significantly better survival in patients with GI-ARL who were concurrently treated with HAART (p =.014). Median survival was 5 months for the no-HAART group and 30 months for the HAART group. CONCLUSION: In patients with GI-ARL who were treated with chemotherapy, concurrent therapy with HAART therapy was associated with improved survival.

Adult↗

PubMedDate not supplied

Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS.

BACKGROUND: Impaired allostimulatory function of dendritic cells in patients with AIDS has been reported previously. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore the T-cell stimulatory function in transforming growth factor-beta 1 (TGF-beta 1)-inhibited murine accessory cells. We now report the effect of intravenous recombinant human GM-CSF (rhGM-CSF) on accessory cells of HIV-infected patients. METHOD: The in vivo effect of GM-CSF on allostimulatory function of accessory cells was evaluated. Seventeen individuals with AIDS received a single infusion of rhGM-CSF (125 mg/m(2) over 120 minutes). Samples of peripheral blood lymphocytes (PBL) were taken at 1, 5, and 24 hours after infusion, and the allostimulatory capacity was measured. RESULTS: A single bolus infusion of rhGM-CSF resulted in significantly increased accessory cell function in 13/17 (88%) patients at one or more assayed time points after infusion. CONCLUSION: These results suggest that the administration of rhGM-CSF can potentially restore allostimulatory function to accessory cells in HIV-infected patients, and this presents a novel way of immune reconstitution. Clinical significance of this approach of immune reconstitution in AIDS patients warrants further investigations.

AIDS Dementia Complex↗

PubMedDate not supplied

Prevention and management of cardiotoxicity from antineoplastic therapy.

Cardiotoxicity is a major side effect of various antineoplastic agents, particularly the anthracyclines. Recently, some of the newer drugs and biologic agents that have been introduced into cancer therapeutics also have been shown to have potential cardiotoxic effects. The spectrum of cardiac side effects varies with the antineoplastic agent, dose, and schedule used. Important risk factors associated with cardiotoxicity are cumulative dose, infusion schedule, and pre-existing cardiac disease. This review focuses on the various adverse cardiovascular events associated with antineoplastic agents, what to anticipate, how to recognize the toxicity, how to prevent and minimize the cardiac side effects, and how to manage the full-blown toxicity if and when it occurs.

Anthracyclines↗